Benzinga · Aug 25, 2026
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.
NR
NASDAQ · NRXP
NRx Pharmaceuticals, Inc.
Healthcare · Biotechnology
$3.49
Up+$0.02 (+0.43%)
Updated Sep 8, 2026, 7:02 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 37.94M
- P/E ratio
- -1.28
- Dividend yield
- 0.00%
- 52-week range
- $1.62 – $5.06
- Volume
- 487.72K
- Avg. volume
- 441.62K
Price performance
NRXP price history
1M range · 20 trading sessions · Daily adjusted prices
NRXP closed at $3.49 after 20 trading sessions, up 4.18% for the selected period.
- Last close
- $3.49
- Period change
- +4.18%
- Period low
- $3.27
- Period high
- $3.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $3.43 | $3.50 | $3.39 | $3.49 | 487.72K |
| Sep 3, 2026 | $3.48 | $3.50 | $3.425 | $3.43 | 237.36K |
| Sep 2, 2026 | $3.46 | $3.50 | $3.38 | $3.46 | 418.34K |
| Sep 1, 2026 | $3.45 | $3.51 | $3.42 | $3.44 | 392.76K |
| Aug 31, 2026 | $3.52 | $3.545 | $3.43 | $3.48 | 427.01K |
| Aug 28, 2026 | $3.63 | $3.68 | $3.50 | $3.55 | 695.6K |
| Aug 27, 2026 | $3.51 | $3.62 | $3.4699 | $3.62 | 584.04K |
| Aug 26, 2026 | $3.62 | $3.62 | $3.38 | $3.46 | 1.01M |
| Aug 25, 2026 | $3.49 | $3.69 | $3.425 | $3.67 | 895.95K |
| Aug 24, 2026 | $3.52 | $3.61 | $3.44 | $3.45 | 898.34K |
| Aug 21, 2026 | $3.52 | $3.60 | $3.44 | $3.56 | 615.3K |
| Aug 20, 2026 | $3.36 | $3.55 | $3.33 | $3.51 | 811.74K |
| Aug 19, 2026 | $3.53 | $3.64 | $3.315 | $3.33 | 713.63K |
| Aug 18, 2026 | $3.39 | $3.47 | $3.28 | $3.44 | 905.07K |
| Aug 17, 2026 | $3.10 | $3.67 | $3.09 | $3.43 | 1.27M |
| Aug 14, 2026 | $3.37 | $3.40 | $3.155 | $3.27 | 1.13M |
| Aug 13, 2026 | $3.41 | $3.63 | $3.315 | $3.34 | 1.24M |
| Aug 12, 2026 | $3.40 | $3.50 | $3.29 | $3.36 | 927.9K |
| Aug 11, 2026 | $3.39 | $3.64 | $3.35 | $3.40 | 1.17M |
| Aug 10, 2026 | $3.51 | $3.64 | $3.31 | $3.35 | 2M |
Latest NRXP news
The latest Smart Investors Daily articles mentioning NRXP.
Stock researchCompany · Overview
NRXP research
Overview
Company profile and research snapshot.
Company profile
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 18, 2026 | BTIG | Buy | — |
| Aug 7, 2026 | BTIG | Buy | — |
| May 5, 2026 | D. Boral Capital | Buy | — |
| Apr 27, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 18, 2026
NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call Transcript
NRx Pharmaceuticals, Inc. (NRXP) Q2 2026 Earnings Call August 17, 2026 4:30 PM EDTCompany ParticipantsJonathan Javitt - Co-Founder, Chairman &...
Benzinga · Aug 17, 2026
NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
NRX Pharmaceuticals (NASDAQ:NRXP) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
Benzinga · Aug 17, 2026
NRX Pharmaceuticals Q2 EPS $(0.44) Misses $0.06 Estimate, Sales $1.101M Miss $17.488M Estimate
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $0.06 by 833.33 percent. This is a 55.1 percent increase over losses of $(0.98) per share
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
